1. Japan Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Toho Holdings Co., Ltd.

Toho Holdings Co., Ltd.

8129.T
Toho Holdings Co., Ltd.JP flagTokyo Stock Exchange
4,012.00
JPY
+53.00
- -
259.58BMarket Cap
Toho Holdings Co., Ltd.
8129.T
(Tokyo Stock Exchange)

Recent

price

4,012.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
14,232.69
14,640.37
15,751.12
15,954.55
15,611.16
19,020.88
17,925.74
17,699.61
18,312.45
18,169.47
17,165.25
17,952.38
20,089.05
22,885.93
23,966.57
24,309.85
11,822.98
Revenue per Share
97.83
142.24
159.2
139.57
181.82
316.51
207.11
209.83
207.71
233.34
70.76
189.69
196.69
320.14
313.2
271.16
189.25
Basic EPS, GAAP
69.79
214.97
175.34
-349.86
336.67
-60.03
109.21
626.86
144.27
-43.92
43.17
172.11
-36.48
870.25
-511.88
152.27
- -
Free Cash Flow per Basic Share
15.9
15.81
16.24
17.7
22.27
25.21
29.96
30.04
30.34
34.89
35
30
31.56
34.64
47.62
85.28
- -
Dividend per Share
924.5
1,032.95
1,225.84
1,268.01
1,430.81
1,840.32
2,020.5
2,202.25
2,436.16
2,536.05
2,546.01
2,706.71
2,917.57
3,415.66
3,623.5
3,772.03
3,581.21
Book Value per Share
1,233.97
1,373.6
1,637.93
1,786.12
1,950.61
2,401.11
2,634.93
2,955.63
3,144.46
3,255.04
3,294.42
3,347.55
3,427.81
3,778.36
3,958.53
4,123.38
4,094.15
Tangible Book Value per Share
74
76
72
75
74
69
69
69
67
70
71
71
69
65
63
64
63
Basic Weighted Avg Shares
1,059,581
1,108,144
1,140,357
1,189,624
1,162,114
1,308,358
1,231,175
1,213,322
1,222,195
1,263,769
1,210,334
1,266,171
1,392,117
1,476,712
1,518,495
1,553,364
741,866
Sales/Revenue/Turnover
1.83
1.27
1.15
1.04
0.85
2.19
1.16
1.57
1.29
1.39
0.36
0.99
1.18
1.31
1.24
1.05
1.73
Operating Margin (%)
3,352
5,174
5,317
6,099
7,272
7,295
6,671
6,455
6,441
5,839
6,796
6,957
6,413
6,514
6,079
6,160
3,095
Depreciation Expense
7,283
10,766
11,526
10,407
13,535
21,771
14,225
14,384
13,863
16,230
4,989
13,379
13,630
20,657
19,844
17,327
11,875
Net Income, GAAP
3.09
43.33
41.22
41.88
37.01
38
34.95
37.99
33.71
33.06
51.43
33.29
33.15
32.85
29.22
33.67
33.07
Effective Tax Rate (%)
0.69
0.97
1.01
0.87
1.16
1.66
1.16
1.19
1.13
1.28
0.41
1.06
0.98
1.4
1.31
1.12
1.6
Profit Margin (%)
24,042
23,813
16,675
25,130
39,855
53,314
58,294
66,897
79,162
99,958
110,194
110,288
93,331
126,583
124,938
129,124
125,419
Working Capital
21,153
15,989
12,509
20,293
30,581
25,805
21,548
24,156
27,526
40,830
40,269
33,596
7,495
29,118
18,953
8,702
19,023
LT Debt
110,916
121,593
134,270
147,188
157,368
174,656
188,270
207,770
213,846
231,007
237,402
241,278
242,915
249,434
256,895
271,557
262,642
Total Equity
12.84
5.17
4.8
4.1
3.19
8.38
4.22
5.12
4.21
4.39
0.74
2.93
3.82
4.53
4.66
3.79
3
Return on Invested Capital (%)
7.66
10.19
10.54
8.82
9.97
14.23
8.71
8.36
7.33
7.71
2.26
5.88
5.79
8.43
7.92
6.91
4.84
Return on Capital (%)
11.05
14.65
13.81
11.36
13.46
18.68
10.72
9.93
8.84
9.58
2.8
7.22
6.93
9.78
8.82
7.36
5.46
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
1,126
- -
525
LT Borrowings
28,166
- -
19,023
LT Finance Leases
952
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
63
- -
65
Market Capitalization
242,102
263,792
284,812

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
597,888
- -
588,234
Cash, Cash Equivalents & STI
132,970
- -
108,227
Accounts Receivable, Net
350,896
- -
339,793
Inventories
87,287
- -
95,671
Total Current Liabilities
471,305
- -
462,815
Payables & Accruals
- -
- -
- -
ST Debt
1,126
- -
525
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.56%
2.74%
5.71%
Free Cash Flow
-264.88%
-486.21%
-130%
Net Income, GAAP
11.56%
41%
-12.68%
Sales/Revenue/Turnover
1.83%
5.15%
2.3%
Total Cash Common Dividend
14.55%
21.38%
80.61%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
351,179
383,667
384,703
357,163
1,476,712
2025
- -
- -
- -
- -
1,518,495
2026
- -
- -
- -
- -
1,553,364

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
23.06
- -
- -
- -
320.14
2025
- -
- -
- -
- -
313.2
2026
- -
- -
- -
- -
271.16

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
34.64
2025
- -
- -
- -
- -
47.62
2026
- -
- -
- -
- -
85.28
Similar Companies
MGC Pharmaceuticals Limited (MXC.AX)
Integrated Pharmaceuticals, Inc. (INTP)
Biofrontera AG (BFFTF)
Indivior PLC (IZQVF)
Orchid Ventures, Inc. (ORCD.CN)
Acerus Pharmaceuticals Corporation (ASPCF)
Business
Toho Holdings Co., Ltd. engages primarily in pharmaceutical wholesaling and related healthcare services in Japan. The company operates through segments including Pharmaceutical Wholesale Business, which distributes prescription pharmaceuticals, over-the-counter drugs, reagents, testing equipment, medical devices, health foods, nursing foods, hygiene materials, sphygmomanometers, blood glucose meters, and dispensing equipment to hospitals, clinics, and pharmacies; Dispensing Pharmacy Business, managing insurance and health-support pharmacies with home medical care, dementia cafes, and advanced pharmaceutical management; Pharmaceutical Manufacturing and Sales Business, producing generic drugs and contract manufacturing injectable pharmaceuticals; and Other Peripheral Businesses, providing clinical trial support via site management organizations, IT solutions such as ENIFwin inventory systems, ENIFvoice electronic medication history tools, ENI-Pharmacy prescription-dispensing systems, LXMATE HeLios and SELENE appointment systems, logistics platforms for specialty drugs like gene therapies, and customer support including medical institution startups, management consulting, and personnel recruitment. Founded in 1948 and headquartered at Tokyo Midtown Yaesu, Yaesu Central Tower 9F, 2-2-1 Yaesu, Chuo-ku, Tokyo, Japan, Toho Holdings lists on the Tokyo Stock Exchange Prime Market (8129.T) and employs 7,609 consolidated staff as of March 31, 2025. Recent developments include a capital and business alliance with PHARUMO, Inc. in 2025, building on their August 2024 business tie-up to integrate PHARUMO's Every series inventory DX solutions and PHARUMO Cloud with Toho's systems for enhanced pharmacy services and community medical DX; a business alliance with WACON Co., Ltd. announced in September 2024; and ongoing specialization in segments like home visitation support and advanced logistics for regenerative medicines.